Prestige Biologics Co., Ltd.
KKRX:3349701,260.00
KRW
+3.00
(+0.24%)
ISIN
KR7334970001
Return %
Stock
S&P 500
1Y
-58.35
14.39
3Y
-73.19
81.42
5Y
-89.00
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Jin-Woo Kim
- Full Time Employees
- 321
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Cheongju-si South Korea
- IPO Date
- Mar 11, 2021
- Website
- prestigebiologics.com
- Similar Companies
- Business
- Prestige Biologics Co., Ltd. is a South Korea-based contract development and manufacturing organization (CDMO) and contract development, engineering, and manufacturing organization (CDEMO) that specializes in the development, engineering, and commercial-scale production of biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and biosimilar therapeutics. Founded in 2015 and headquartered in Cheongju-si, Chungcheongbuk-do, South Korea, the company operates biomanufacturing campuses within the Osong Bio Valley, providing end-to-end outsourcing solutions to domestic and international pharmaceutical and biotechnology enterprises. The company offers a comprehensive suite of biomanufacturing services comprising cell line development; upstream and downstream bioprocess development; analytical method development and quality validation; formulation development and stability testing; cGMP-compliant drug substance (DS) manufacturing; aseptic fill-finish drug product (DP) manufacturing; single-use bag and bioprocessing equipment engineering; and turnkey biopharmaceutical facility design and construction consulting. Prestige Biologics utilizes its proprietary ALITA Smart BioFactory system, an engineering-driven hybrid manufacturing platform combining single-use bioreactor technology with automated piping and stainless-steel architecture to minimize cross-contamination risk, lower production costs, and accelerate batch changeover cycles. The company manufactures commercial and clinical-stage biologics, including biosimilar and innovative drug candidates developed in collaboration with its Singapore-based affiliate Prestige BioPharma, such as HD201 (trastuzumab biosimilar), HD204 (bevacizumab biosimilar), and PBP1510 (anti-PAUF monoclonal antibody). In recent developments, Prestige Biologics completed the construction and operational validation of its Plant 4 manufacturing facility, scaling its aggregate bioreactor capacity to approximately 154,000 liters and positioning the firm among the largest biomanufacturing organizations in South Korea. The company has also expanded its global commercial operations by formalizing its CDEMO service model, securing multi-year drug substance supply and clinical batch manufacturing agreements with international biopharma partners, and initiating commercial-scale technology transfer protocols aligned with regulatory approvals and distribution partnerships across Europe, North America, and emerging markets.